Mineralys Therapeutics Financial Statements
NASDAQ: MLYSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
23.37+0.99 (+4.42%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mineralys Therapeutics revenue and earnings
Mineralys Therapeutics reported a net loss of $154.7 million, compared with a loss of $177.8 million a year earlier. Diluted earnings per share came in at -$2.29.
Summary generated from market data by MetaCap's automated system. Methodology
Mineralys Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 |
|---|---|---|---|---|
| Operating Expenses | 170.60M | 192.40M | 84.66M | 31.48M |
| Research & Development | 132.01M | 168.58M | 70.36M | 26.25M |
| Operating Income | -170.60M | -192.40M | -84.66M | -31.48M |
| Other Income (Expense) | 15.95M | 14.59M | 12.76M | 1.68M |
| Income Tax | 0 | — | — | — |
| Net Income | -154.65M | -177.81M | -71.90M | -29.80M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -2.29 | -3.66 | -1.99 | -5.77 |
| EPS (Diluted) | -2.29 | -3.66 | -1.99 | -5.77 |
| Shares Outstanding (Basic) | 67.66M | 48.54M | 36.19M | 5.17M |
| Shares Outstanding (Diluted) | 67.66M | 48.54M | 36.19M | 5.17M |
| EBITDA | -170.54M | -192.36M | -84.66M | — |
This table shows 4 annual periods of Mineralys Therapeutics's income statement, from FY 2025 back to FY 2022, across 11 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow MLYS's reporting calendar. What is a income statement?